Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENLIGHTEN-6: eloralintide added to weekly incretin therapy in adults with persistent obesity or overweight
2025-523659-73-00Phase 3Authorised
- Sponsor
- Eli Lilly and Company
- Start
- May 2026
- Modality
- Peptides
- Countries
- 13
01
Overview
Phase 3, randomised, double-blind trial in obesity and Overweight comparing Eloralintide + weekly incretin therapy with Placebo + weekly incretin therapy (2 arms). Primary endpoint: Percent change from baseline in body weight. Planned start May 2026; status: authorised.
02
Drugs
eloralintide
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on 2025-523659-73-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523659-73-00.